TP53: Coordinator of the Processes That Underlie the Hallmarks of Cancer
暂无分享,去创建一个
[1] S. Kyo,et al. Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] P. Bénit,et al. AIF deficiency compromises oxidative phosphorylation , 2004, The EMBO journal.
[3] David Beach,et al. Glycolytic enzymes can modulate cellular life span. , 2005, Cancer research.
[4] P. Hainaut,et al. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma , 2008, Molecular carcinogenesis.
[5] A. Levine,et al. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function , 2010, Proceedings of the National Academy of Sciences.
[6] A. Mes-Masson,et al. p53 inhibits angiogenesis by inducing the production of Arresten. , 2012, Cancer research.
[7] E. Morselli,et al. Defective autophagy control by the p53 rheostat in cancer , 2010, Cell cycle.
[8] A. McClatchey,et al. Nf2/Merlin: a coordinator of receptor signalling and intercellular contact , 2007, British Journal of Cancer.
[9] V. de Laurenzi,et al. p63/p73 in the control of cell cycle and cell death. , 2012, Experimental cell research.
[10] U. Moll,et al. The transcription-independent mitochondrial p53 program is a major contributor to Nutlin-induced apoptosis in tumor cells , 2009, Cell cycle.
[11] C. Harris,et al. Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[12] Gerard I. Evan,et al. Modeling the Therapeutic Efficacy of p53 Restoration in Tumors , 2006, Cell.
[13] K. Ryan,et al. DRAM Links Autophagy to p53 and Programmed Cell Death , 2007, Autophagy.
[14] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[15] Y. Zou,et al. XPA-Mediated Regulation of Global Nucleotide Excision Repair by ATR Is p53-Dependent and Occurs Primarily in S-Phase , 2011, PloS one.
[16] K. Vousden,et al. Role of NF-κB in p53-mediated programmed cell death , 2000, Nature.
[17] M. Blasco,et al. A p53-Dependent Response Limits Epidermal Stem Cell Functionality and Organismal Size in Mice with Short Telomeres , 2009, PloS one.
[18] V. Rotter,et al. Structural and functional involvement of p53 in BER in vitro and in vivo , 2001, Oncogene.
[19] Yusuke Nakamura,et al. Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses , 2004, Journal of Human Genetics.
[20] Michael K. Wendt,et al. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. , 2009, Future oncology.
[21] Zhaohui Feng,et al. p53 regulation of the IGF-1/AKT/mTOR pathways and the endosomal compartment. , 2010, Cold Spring Harbor perspectives in biology.
[22] L. Strong,et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.
[23] B. Walker,et al. From sentencing to execution – the processes of apoptosis , 2010, The Journal of pharmacy and pharmacology.
[24] L. Chin,et al. Telomere dysfunction induces metabolic and mitochondrial compromise , 2011, Nature.
[25] E. Morselli,et al. Stimulation of autophagy by the p53 target gene Sestrin2 , 2009, Cell cycle.
[26] Pierre Hainaut,et al. Massively regulated genes: the example of TP53 , 2010, The Journal of pathology.
[27] T. Brabletz. MiR-34 and SNAIL: Another double-negative feedback loop controlling cellular plasticity/EMT governed by p53 , 2012, Cell cycle.
[28] S. Velasco-Miguel,et al. Induction of the growth inhibitor IGF-binding protein 3 by p53 , 1995, Nature.
[29] Michael R. Green,et al. p53-Mediated Inhibition of Angiogenesis Through Up-Regulation of a Collagen Prolyl Hydroxylase , 2006, Science.
[30] J. Marine,et al. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice , 2008, Cell Death and Differentiation.
[31] M. Oren,et al. New plays in the p53 theater. , 2011, Current opinion in genetics & development.
[32] Angel Porgador,et al. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. , 2011, Cancer research.
[33] Pierre Hainaut,et al. Next-generation sequencing: emerging lessons on the origins of human cancer , 2011, Current opinion in oncology.
[34] B. Seliger,et al. Upregulation of Major Histocompatibility Complex Class I on Liver Cells by Hepatitis C Virus Core Protein via p53 and TAP1 Impairs Natural Killer Cell Cytotoxicity , 2003, Journal of Virology.
[35] James M. Roberts,et al. CDK inhibitors: positive and negative regulators of G1-phase progression. , 1999, Genes & development.
[36] Samy Lamouille,et al. TGF-β-induced epithelial to mesenchymal transition , 2009, Cell Research.
[37] L. Wiesmüller,et al. p53 in recombination and repair , 2006, Cell Death and Differentiation.
[38] Tim Crook,et al. Functional regulation of p73 and p63: development and cancer. , 2003, Trends in biochemical sciences.
[39] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[40] R. Abraham,et al. The autophagy conundrum in cancer: influence of tumorigenic metabolic reprogramming , 2011, Oncogene.
[41] M. Olivier,et al. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome , 2010, Current opinion in oncology.
[42] Eyal Gottlieb,et al. TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.
[43] W. El-Deiry,et al. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth, and chemosensitivity under hypoxic conditions , 2009, Cell cycle.
[44] D. Menendez,et al. The Toll-Like Receptor Gene Family Is Integrated into Human DNA Damage and p53 Networks , 2011, PLoS genetics.
[45] B. Kaina,et al. p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents , 1998, Oncogene.
[46] Hongtae Kim,et al. Merlin Neutralizes the Inhibitory Effect of Mdm2 on p53* , 2004, Journal of Biological Chemistry.
[47] R. Baxter,et al. The IGF axis and programmed cell death , 1999, Immunology and cell biology.
[48] D. Trinh,et al. Direct interaction between p53 and Tid1 proteins affects p53 mitochondrial localization and apoptosis , 2010, Oncotarget.
[49] Robert S. Balaban,et al. p53 Improves Aerobic Exercise Capacity and Augments Skeletal Muscle Mitochondrial DNA Content , 2009, Circulation research.
[50] M. Armoni,et al. The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression , 2004, Cancer Research.
[51] p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs , 2010, Nature Cell Biology.
[52] M. Oren,et al. Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[53] A. Børresen-Dale,et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.
[54] B. Vojtesek,et al. The role of P63 in cancer, stem cells and cancer stem cells , 2011, Cellular & Molecular Biology Letters.
[55] P. Hainaut,et al. Redox control and interplay between p53 isoforms: roles in the regulation of basal p53 levels, cell fate, and senescence. , 2011, Antioxidants & redox signaling.
[56] V. Rotter,et al. Mutant p53R175H upregulates Twist1 expression and promotes epithelial–mesenchymal transition in immortalized prostate cells , 2011, Cell Death and Differentiation.
[57] P. Hainaut,et al. Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity , 2005, Oncogene.
[58] S. Weitzman,et al. Chronic inflammation and cancer: the role of the mitochondria. , 2011, Oncology.
[59] D. Schadendorf,et al. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. , 2012, Cancer research.
[60] D. Trinh,et al. Tid1 is a new regulator of p53 mitochondrial translocation and apoptosis in cancer , 2010, Oncogene.
[61] Uri Tabori,et al. Excessive genomic DNA copy number variation in the Li–Fraumeni cancer predisposition syndrome , 2008, Proceedings of the National Academy of Sciences.
[62] L. Donehower,et al. The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. , 2004, Molecular cell.
[63] R. Maestro,et al. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. , 2008, Cancer cell.
[64] Ronald A. DePinho,et al. Linking functional decline of telomeres, mitochondria and stem cells during ageing , 2010, Nature.
[65] S. Sommer,et al. Most spontaneous tumors in a mouse model of Li-Fraumeni syndrome do not have a mutator phenotype. , 2006, Carcinogenesis.
[66] Y. Zou,et al. Differential DNA damage responses in p53 proficient and deficient cells: cisplatin-induced nuclear import of XPA is independent of ATR checkpoint in p53-deficient lung cancer cells. , 2011, International journal of biochemistry and molecular biology.
[67] D. Lyden,et al. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. , 2011, Seminars in cancer biology.
[68] D. Trinh,et al. Direct interaction between p53 and Tid1 proteins affects p53 mitochondrial localization and apoptosisy as a Target for Cancer Therapy , 2010 .
[69] David Lane,et al. p53 Research: the past thirty years and the next thirty years. , 2010, Cold Spring Harbor perspectives in biology.
[70] Sam W. Lee,et al. p53 Serves as a Host Antiviral Factor That Enhances Innate and Adaptive Immune Responses to Influenza A Virus , 2011, The Journal of Immunology.
[71] B. Goud,et al. TSAP6 Facilitates the Secretion of Translationally Controlled Tumor Protein/Histamine-releasing Factor via a Nonclassical Pathway* , 2004, Journal of Biological Chemistry.
[72] M. Weller,et al. Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death , 2012, Oncogene.
[73] E. Abraham,et al. p53 Attenuates Lipopolysaccharide-Induced NF-κB Activation and Acute Lung Injury 1 , 2009, The Journal of Immunology.
[74] M. Swaroop,et al. Transcriptional Activation of the Human Glutathione Peroxidase Promoter by p53* , 1999, The Journal of Biological Chemistry.
[75] P. Hainaut,et al. 30 years and a long way into p53 research. , 2009, The Lancet. Oncology.
[76] Nobuyuki Tanaka,et al. p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation , 2008, Nature Cell Biology.
[77] V. Rotter,et al. Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells , 2010, The Journal of experimental medicine.
[78] Kyu-Won Kim,et al. Hypoxia-induced angiogenesis during carcinogenesis. , 2003, Journal of biochemistry and molecular biology.
[79] M. Blasco,et al. p53 Prevents Entry into Mitosis with Uncapped Telomeres , 2010, Current Biology.
[80] B. Kopnin,et al. p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. , 2009, Cancer letters.
[81] A. Levine,et al. Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway , 2012, Cell.
[82] L. Donehower,et al. Homeostatic Regulation of Base Excision Repair by a p53-Induced Phosphatase: Linking Stress Response Pathways with DNA Repair Proteins , 2004, Cell cycle.
[83] Qing Gao,et al. Endogenous LKB1 knockdown accelerates G1/S transition through p53 and p16 pathways , 2010, Cancer biology & therapy.
[84] P. Raychaudhuri,et al. Tumor suppression by ARF: Gatekeeper and caretaker , 2010, Cell cycle.
[85] D. Lane,et al. p53, guardian of the genome , 1992, Nature.
[86] Carlos Cordon-Cardo,et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.
[87] M. Oren,et al. Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.
[88] J. Shay,et al. Telomeres and Telomerase: Implications for Cancer and Aging , 2001, Radiation research.
[89] Samy Lamouille,et al. Oncogene and tumour suppressor: the two faces of SnoN , 2009, EMBO Journal.
[90] J. Zhuang,et al. p53: exercise capacity and metabolism , 2012, Current opinion in oncology.
[91] Kevin M. Ryan,et al. DRAM, a p53-Induced Modulator of Autophagy, Is Critical for Apoptosis , 2006, Cell.
[92] M. Olivier,et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models , 2011, Cell Death and Differentiation.
[93] W P Bennett,et al. Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. , 1999, Journal of the National Cancer Institute.
[94] K. Helin,et al. Suppression of the p53- or pRB-mediated G1 checkpoint is required for E2F-induced S-phase entry , 2002, Nature Genetics.
[95] Y. Yin,et al. PTEN: a new guardian of the genome , 2008, Oncogene.
[96] E. Gottlieb,et al. p53 regulation of metabolic pathways. , 2010, Cold Spring Harbor perspectives in biology.
[97] Lixin Wei,et al. Epithelial-Mesenchymal Transition in tumor microenvironment , 2011, Cell & Bioscience.
[98] D. Andrews,et al. BH3-only proteins: Orchestrators of apoptosis. , 2011, Biochimica et biophysica acta.
[99] C. Harris,et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[100] A. Chatterjee,et al. The effect of p53‐RNAi and p53 knockout on human 8‐oxoguanine DNA glycosylase (hOgg1) activity , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[101] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.
[102] P. Hainaut,et al. Cross‐talks between cyclooxygenase‐2 and tumor suppressor protein p53: Balancing life and death during inflammatory stress and carcinogenesis , 2007, International journal of cancer.
[103] A. Mancuso,et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase , 2011, Nature Cell Biology.
[104] W. El-Deiry,et al. KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death. , 2000, Advances in experimental medicine and biology.